309 related articles for article (PubMed ID: 21215811)
1. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.
Pidala J; Tomblyn M; Nishihori T; Ayala E; Field T; Fernandez H; Perez L; Locke F; Alsina M; Ochoa JL; Perkins J; Tate C; Shapiro J; Conwell M; Bookout R; Anasetti C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1237-44. PubMed ID: 21215811
[TBL] [Abstract][Full Text] [Related]
2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
3. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
4. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
5. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
6. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
8. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
[TBL] [Abstract][Full Text] [Related]
9. Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.
Al-Kadhimi Z; Gul Z; Rodriguez R; Chen W; Smith D; Mitchell A; Abidi M; Ayash L; Deol A; Lum L; Forman S; Ratanatharathorn V; Uberti J
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1734-44. PubMed ID: 22710143
[TBL] [Abstract][Full Text] [Related]
10. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
11. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies.
Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402
[TBL] [Abstract][Full Text] [Related]
12. Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation.
Wang H; Zhao Y; Fang S; Wang L; Peng B; Yang J; Wang N; Du J; Li F; Jin X; Luan S; Wu X; Dou L; Liu D
Transplant Cell Ther; 2022 Jun; 28(6):332.e1-332.e10. PubMed ID: 35314377
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Oncol; 2016 Feb; 17(2):164-173. PubMed ID: 26723083
[TBL] [Abstract][Full Text] [Related]
14. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
[TBL] [Abstract][Full Text] [Related]
16. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin.
Finke J; Schmoor C; Lang H; Potthoff K; Bertz H
J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442
[TBL] [Abstract][Full Text] [Related]
17. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
18. Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S; Cerrano M; Brunello L; Dellacasa CM; Faraci DG; Vassallo S; Mordini N; Sorasio R; Zallio F; Busca A; Bruno B; Giaccone L
Ann Hematol; 2021 Jul; 100(7):1837-1847. PubMed ID: 33948721
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation.
Mountjoy L; Jain T; Kunze KL; Khera N; Sproat LZ; Jennifer W; McCallen M; Leis JF; Noel P; Slack JL; Palmer J
Leuk Lymphoma; 2020 Aug; 61(8):1996-2002. PubMed ID: 32281491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
